linjc16/ctgov huggingface dataset:
Role of Glycation and Inflammation in Acute Ischemic Heart Disease

Study Overview
=================
Brief Summary
-----------------
This study requires the consecutive enrollment of 60 patients following the first event of acute myocardial infarction, evaluating B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting (pre-reperfusion) and 3 months after reperfusion.

Detailed Description
-----------------
This study requires the consecutive enrollment of 60 patients at admission for first acute myocardial infarction. At enrollment, before reperfusion, a blood sample is obtained to measure B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting. This measure is then repeated at follow-up visit 3 months after reperfusion. The aim of the study is to identify specific subsets of patients and evaluate biomarkers variations.

Official Title
-----------------
Action of Glycation and Inflammation in Operative Ischemic Heart Disease

Conditions
-----------------
Inflammation, Myocardial Infarction, Glycation End Products, Advanced, Heart Injuries, Heart Inflammation

Intervention / Treatment
-----------------
* Diagnostic Test: BAFF and MGO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hospitalization for first myocardial infarction (STEMI or NSTEMI) age between 18 and 80 Exclusion Criteria: uncompensated T2DM (HbA1c >53mmol/mol) use of anti-CD20 treatment chronic anti-inflammatory treatment for autoimmune disease (i.e. DMARDs, high dose FANS, cortisonic drugs)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| First Ischemic Cardiac Event<br>Measurement of BAFF and MGO at hospitalization (before reperfusion) and after 3 months during follow-up | Diagnostic Test: BAFF and MGO<br>* measurement of BAFF and MGO levels before reperfusion and after 3 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of Inflammatory Biomarkers (BAFF) linked to ischemic event and outcome | elevation of BAFF levels | Day 0 | 
| Identification of Glycation Biomarkers (MGO) linked to ischemic event and outcome | elevation of MGO levels | Day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of biomarkers variations (BAFF) complications and outcome | variation of BAFF from baseline | After 3 months | 
| Identification of biomarkers variations (MGO) complications and outcome | variation of MGO from baseline | After 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AGEs, BAFF, Myocardial Infarction
Results of Sleeve Gastrectomy Surgery in Relation With Eating Habits (After One Year)

Study Overview
=================
Brief Summary
-----------------
Sleeve gastrectomy is one of the most common surgical procedures performed today for patients that undergo bariatric surgery. One of the primary reasons for morbid obesity is unhealthy eating habits and the belief that changes in those habits can ensure the success. Objectives: The investigators aimed to explore the effect of different eating habits prior to the bariatric surgery on the surgery success and on different aspect of quality of life. Design: The investigators conducted this study on patients that underwent sleeve gastrectomy as the first bariatric operation.

Detailed Description
-----------------
The investigators conducted this study on patients that underwent sleeve gastrectomy as the first bariatric operation. The investigators divided the patients into groups according to their pre-operation eating habits: binge, sweet, snack and high volume and compared different aspects of the surgery such as weight loss, BMI and distance from ideal weight. The investigators also examined the effect of the surgery on the quality of life, sexual life, physical activity, eating habits and satisfaction from the surgery by a telephonic survey that was conducted up to one year after the surgery.

Official Title
-----------------
The Effect of Different Eating Habits on Weight Loss in the First Year After Sleeve Gastrectomy

Conditions
-----------------
Other Habit and Impulse Disorders, Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: morbid obesity approved for bariatric surgery by the hospital's committee Patients that underwent primary surgery Exclusion Criteria: recurrent surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Binge eaters<br>Classificated preoperatively | |
| Volume eaters<br>Classificated preoperatively | |
| sweet eaters<br>Classificated preoperatively | |
| snack eaters<br>Classificated preoperatively | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| weight loss | measured in KG | one year |
Acupuncture in Stroke Rehabilitation

Study Overview
=================
Brief Summary
-----------------
The primary purpose of the study is to examine the effect of acupuncture treatment when combined with strength training on the motor functional recovery of stroke survivors

Detailed Description
-----------------
In this study, we compare the effect on motor functional improvement between a combined acupuncture and strength training program and the strength training alone. The results may allow us to determine whether the acupuncture may bring in additional benefit to the motor recovery in the upper limb in stroke survivors

Official Title
-----------------
Electro-acupuncture and Strengthening Exercise for Hemiplegic Elbow and Wrist Joints

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Other: Acupuncture and Strengthening
* Other: Strengthening Alone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: After stroke (>6 months) Exclusion Criteria: Other neurological diseases

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Acupuncture and strength training | Other: Acupuncture and Strengthening<br>* Acupuncture and strengthening<br>|
| Other: 2<br>Strength training | Other: Strengthening Alone<br>* Strengthening training program<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fugl-Meyer Motor Scores |  | Before and After 6 Week Treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Active wrist ROM |  | Before and After 6 Week Treatment | 
| Quantitative Measure of Muscle Spasticity |  | Before and After 6 Week Treatment | 
| Ashworth Score |  | Before and After 6 Week Treatment |
The Evolving Use of Robotic Surgery

Study Overview
=================
Brief Summary
-----------------
A retrospective, population-based analysis examining the rates of robotic surgery between the years of 2009 - 2018.

Detailed Description
-----------------
A retrospective, population-based analysis examining the rates of robotic surgery in Ontario between the years of 2009 - 2018. The purposes of the study were (i) to describe temporal trends and (ii) patient- and system-level determinants of receiving robotic compared to open or laparoscopic surgery.

Official Title
-----------------
The Evolving Use of Robotic Surgery: A Population-based Analysis

Conditions
-----------------
Surgery

Intervention / Treatment
-----------------
* Procedure: Robotic Surgery
* Procedure: Open Surgery
* Procedure: Laparoscopic Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Minimum 18 years old Received an elective radical prostatectomy, total hysterectomy, partial nephrectomy, or thoracic lobectomy using an open, laparoscopic or robotic approach between 2008-2018 Exclusion Criteria: Non-Ontario residents Non-elective procedure Patients without OHIP eligibility Patients who had an identical procedure in the previous two years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Radical prostatectomies<br> | Procedure: Robotic Surgery<br>* Surgical procedure using robotic technologies.<br>Procedure: Open Surgery<br>* Surgical procedure using a large, open cut in the skin.<br>Procedure: Laparoscopic Surgery<br>* Surgical procedure using small incisions and trochars.<br>|
| Total hysterectomies<br> | Procedure: Robotic Surgery<br>* Surgical procedure using robotic technologies.<br>Procedure: Open Surgery<br>* Surgical procedure using a large, open cut in the skin.<br>Procedure: Laparoscopic Surgery<br>* Surgical procedure using small incisions and trochars.<br>|
| Thoracic lobectomies<br> | Procedure: Robotic Surgery<br>* Surgical procedure using robotic technologies.<br>Procedure: Open Surgery<br>* Surgical procedure using a large, open cut in the skin.<br>Procedure: Laparoscopic Surgery<br>* Surgical procedure using small incisions and trochars.<br>|
| Partial nephrectomies<br> | Procedure: Robotic Surgery<br>* Surgical procedure using robotic technologies.<br>Procedure: Open Surgery<br>* Surgical procedure using a large, open cut in the skin.<br>Procedure: Laparoscopic Surgery<br>* Surgical procedure using small incisions and trochars.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Temporal trends | To describe temporal trends in robotic surgery | 2009 - 2018 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Robotic surgery
Prevalence of Femoroacetabular Impingement in Asymptomatic Patients

Study Overview
=================
Brief Summary
-----------------
Femoroacetabular hip impingement syndrome is a newly recognized cause of early arthritis of the hip. In this condition a variation in the shape of the upper thigh bone causes it to repeatedly come in contact with the hip socket leading to cartilage damage and arthritis. The purpose of this study is to investigate whether patients without hip pain have variations at the hip joint such as those seen in hip impingement syndrome.

Detailed Description
-----------------
Participants in this study will be asked to come to the hospital after regular work hours for an MRI of the hip joints. Prior to the MRI, a physician will perform a range of motion check of the participants hips. The MRI will take approximately 20 minutes during which the participant will have to lie still in a closed space. Participants will receive a letter which can be forwarded to their family doctor if the MRI has any abnormal findings including signs of hip impingement.

Official Title
-----------------
Prevalence of Femoroacetabular Impingement in Asymptomatic Patients

Conditions
-----------------
Femoroacetabular Hip Impingement Syndrome

Intervention / Treatment
-----------------
* Radiation: Magnetic resonance imaging (MRI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No hip problems No containdications to MRI Exclusion Criteria: - Patient does not meet above criteria

Ages Eligible for Study
-----------------
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Asymptomatic patients<br>Asymptomatic, healthy patients (without hip pain or prior hip disease) will be recruited. Patients will undergo a magnetic resonance imaging (MRI) of the hip joints to evaluate for the prevalence of femoroacetabular impingement (FAI). | Radiation: Magnetic resonance imaging (MRI)<br>* Participation in this study will involve patients coming to the hospital after regular work hours for an MRI of the hip joints.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Femoroacetabular Impingement (FAI) | Prevalence of femoroacetabular impingement (FAI), a newly recognized cause of early arthritis of the hip, will be investigated by means of hip MRI to evaluate for abnormal morphology of the anterior head-neck junction of the femur. Participant MRIs were reviewed by two independent radiologists. The prevalence of FAI was calculated as determined by an abnormal alpha angle (greater than 50.5 degrees). | Pre-operative on Day of MRI | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
femoroacetabular impingement
Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is to investigate the safety of intravitreal (IVT) REGN2176-3 in patients with neovascular wet age-related macular degeneration (AMD).

Conditions
-----------------
Neovascular Wet Age-related Macular Degeneration (AMD)

Intervention / Treatment
-----------------
* Drug: REGN2176-3


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Key Criteria: Men or women greater than or equal to 50 years of age who provide informed consent and have active subfoveal choroidal neovascularization (CNV) secondary to wet AMD. Exclusion Criteria: Any prior treatment with an inhibitor of PDGF (platelet-derived growth factor) or PDGFR (platelet-derived growth factor receptor) Active neovascular AMD in the fellow eye requiring treatment Scar, fibrosis, or atrophy in the study eye involving the center of the fovea Presence of retinal pigment epithelial tears or rips involving the macula in the study eye Prior vitrectomy in the study eye Any history of macular hole of stage 2 and above in the study eye Any intraocular or periocular surgery within 3 months of day 1 in the study eye, except lid surgery History of corneal transplant in the study eye Positive serum human chorionic gonadotropin (hCG)/ urine pregnancy test at the screening or baseline visit The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial and not all inclusion/ exclusion criteria are listed.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohorts 1 - 4<br>Participants in cohort 1 will receive REGN2176-3 dosing regimen 1. Participants in cohort 2 will receive REGN2176-3 dosing regimen 2. Participants in cohort 3 will receive REGN2176-3 dosing regimen 3. Participants in cohort 4 will receive REGN2176-3 dosing regimen 4. | Drug: REGN2176-3<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety | The primary endpoint in the study is the incidence of treatment emergent adverse events (TEAEs) from day 1 through week 24 in patients treated with IVT REGN2176-3. | day 1 through week 24 |
E-MAX 2nd Gen Vit E Poly On BIOLOX Delta Ceramic Heads

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to monitor outcomes of total hip arthroplasties performed with E-MAX polyethylene and BIOLOX Delta Ceramic head. Polyethylene has been used as a bearing surface in total joint replacements for half of a century. Radiation, the most common form of sterilization, unfortunately it results in the creation of free radicals (atoms or molecules that cause chemical reactions with other substances) within the materials which cause the breakdown of the polyethylene. Second generation antioxidant polyethylene, Renovis E-MAX, mechanically blends in Vitamin E as an antioxidant. This helps eliminate free radicals while maintaining mechanical strength. The theory is that E-MAX will be a safe and long lasting bearing surface in total hip arthroplasty that meets or exceeds current wear rates after being placed in a patient.

Official Title
-----------------
E-MAX 2nd Generation Vitamin E Polyethylene On BIOLOX Delta Ceramic Heads

Conditions
-----------------
In Need of a Total Hip Arthroplasty

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is under 65 years of age Patient's health status qualifies as ASA 1 or ASA 2 Patient is willing to commit to long term follow (study duration is 10 yrs) Exclusion Criteria: Allergy to any materials used in hip implant Unwillingness to participate in long term follow-up Diagnosis of inflammatory arthritis Simultaneous bilateral total hip arthroplasty is recommended. Patient's health status qualifies as ASA 3 or greater. Patient is over the age of 65 of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| E-Max liner wear rate | This measure's purpose it to look at the longevity of our product. Radiographs will be taken at standard checkpoints over the course of 10 years. Radiographic analysis will be done to assess wear rates of the E-Max liner over the course of the 10 year study. Wear rates will then be compared to other products that have already been studied and published in hopes of finding that E-Max's wear rates are at least as good if not better than comparative products on the market. | Change from baseline to 10 years post-operative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Function and Mobility | This measure will assess patient function and mobility preoperatively and compare this at standard checkpoints over 10 years post-operatively. This will be done through use of the Harris Hip Score and UCLA Functional Assessment with the hope of seeing improvement in both over the course of time. | Change from Pre-operative to 10 years post-operative |
Mainz Intracoronary Database. The Coronary Slow-flow and Microvascular Diseases Registry

Study Overview
=================
Brief Summary
-----------------
Primary goal of the registry is to collect prospective data on patients undergoing coronary angiography in Mainz. Following amendment of the procol, this study will also include patients who received an Aborb bioresorbable scaffold for the therapy of de novo stenoses.

Detailed Description
-----------------
Patients included in the registry will be contacted by telephone at 3,6,9, 12 months and 2, 5, 10 years after the procedure. In case coronary slow flow is shown at the index procedure, 39ml of blood will be drawn for further studies. According to the regulations of the Province Rheinland-Pfalz, national law, and with the approval of the Ethic commission of the Landesärztekammer Rheinland Pfalz, patients (n=1000) will also be retrospectively entered in the database in an anonymous way. For these patients, no specific study procedure is foreseen and the MICAT database will be only used as a platform (database of anonymous data collected during routine clinical practice).

Official Title
-----------------
Mainzer IntraCoronAry daTabase (MICAT). Das Coronary Slow Flow- Syndrom Und Koronare Mikrozirkulationsstörungen- Register.

Conditions
-----------------
Coronary Artery Disease, Microvascular Dysfunction

Intervention / Treatment
-----------------
* Other: observational only- no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical indication to coronary angiography Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Consecutive patients undergoing coronary angiography<br>Consecutive patients undergoing coronary angiography at the University Medical Center Mainz - no inclusion criteria specified. The absorb substudy will include consecutive patients who received an Absorb scaffold based on clinical indication. | Other: observational only- no intervention<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiovascular events | Incidence of major adverse events (death, death of cardiac cause, TLR - target lesion revascularization, MI) | baseline to 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Individual endpoints | Each individual endpoint of the MACE previously described | baseline to 10 years | 
| Other cardiovascular endpoints | TVR - target vessel revascularization, re-hospitalization, change in medications. | baseline to 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
microvascular disease, coronary artery disease, Coronary artery disease, with or without microvascular dysfuntion